Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aehr Test Systems (AEHR) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance

Aehr Test SystemsTrade
Bio-Rad Laboratories, Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Aehr Test Systems vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Aehr Test Systems trades at $130.74 (market cap $3.82B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $352.08 (market cap $9.43B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 2.5× Aehr Test Systems's market cap, and Aehr Test Systems is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.

AEHRBIO
Market Cap
$3.82B$9.43B
Sector
TechnologyHealth
52-Week High
$117.18$356.25
52-Week Low
$17.38$241.71
Enterprise Value
$3.72B$9.18B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aehr Test Systems

AEHR Test Systems stock trades at $129.70, up 22.13% in the past 24 hours, with a bullish technical signal from moving averages and strong momentum. Recent earnings beats and a $22 million AI processor order (Accesswire, August 12, 2026) highlight growth potential, though negative net income margins and high P/S of 71.87 reflect valuation concerns amid rapid revenue expansion.

Outlook is mixed: strong AI-driven demand and record bookings support upside, but profitability challenges, insider selling, and customer concentration pose risks. Analyst consensus is cautious with 33% buy ratings, indicating tempered optimism despite technical strength.

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.

BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aehr Test Systems

Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.

Read more on AEHR

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO